Related references
Note: Only part of the references are listed.Pedunculopontine Nucleus Cholinergic Deficiency in Cervical Dystonia
Karin Mente et al.
MOVEMENT DISORDERS (2018)
M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition
Sean P. Moran et al.
NEUROPSYCHOPHARMACOLOGY (2018)
Heterozygous Gnal Mice Are a Novel Animal Model with Which to Study Dystonia Pathophysiology
Assunta Pelosi et al.
JOURNAL OF NEUROSCIENCE (2017)
Parkinsonism Without Dopamine Neuron Degeneration in Aged L-Dopa-Responsive Dystonia Knockin Mice
Samuel J. Rose et al.
MOVEMENT DISORDERS (2017)
Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor
Mark S. Moehle et al.
NEURON (2017)
Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders
Daniel J. Foster et al.
NEURON (2017)
Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model
A. Ghoshal et al.
NEUROPSYCHOPHARMACOLOGY (2016)
Cell-Type-Specific Control of Brainstem Locomotor Circuits by Basal Ganglia
Thomas K. Roseberry et al.
CELL (2016)
Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease
Samira Ztaou et al.
JOURNAL OF NEUROSCIENCE (2016)
Cholinergic Mesopontine Signals Govern Locomotion and Reward through Dissociable Midbrain Pathways
Cheng Xiao et al.
NEURON (2016)
Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release
Daniel J. Foster et al.
NEURON (2016)
Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine Modulation
Claudia Rangel-Barajas et al.
JOURNAL OF HUNTINGTONS DISEASE (2016)
Role for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice
R. W. Gould et al.
ACS CHEMICAL NEUROSCIENCE (2015)
Diagnosis and Treatment of Dystonia
H. A. Jinnah et al.
NEUROLOGIC CLINICS (2015)
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia
Weixing Shen et al.
NEURON (2015)
Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice
Tristano Pancani et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Forebrain deletion of the dystonia protein torsinA causes dystonic-like movements and loss of striatal cholinergic neurons
Samuel S. Pappas et al.
ELIFE (2015)
Behavioral and Electrophysiological Characterization of Dyt1 Heterozygous Knockout Mice
Fumiaki Yokoi et al.
PLOS ONE (2015)
Dopamine Receptor and Ga(olf) Expression in DYT1 Dystonia Mouse Models during Postnatal Development
Lin Zhang et al.
PLOS ONE (2015)
The M1 Muscarinic Positive Allosteric Modulator PQCA Improves Performance on Translatable Tests of Memory and Attention in Rhesus Monkeys
Henry S. Lange et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
M4 mAChR-Mediated Modulation of Glutamatergic Transmission at Corticostriatal Synapses
Tristano Pancani et al.
ACS CHEMICAL NEUROSCIENCE (2014)
Selective Activation of M4 Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents
Michael Bubser et al.
ACS CHEMICAL NEUROSCIENCE (2014)
Pharmacological Treatment of Parkinson Disease A Review
Barbara S. Connolly et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
A Major External Source of Cholinergic Innervation of the Striatum and Nucleus Accumbens Originates in the Brainstem
Daniel Dautan et al.
JOURNAL OF NEUROSCIENCE (2014)
M5 Receptor Activation Produces Opposing Physiological Outcomes in Dopamine Neurons Depending on the Receptor's Location
Daniel J. Foster et al.
JOURNAL OF NEUROSCIENCE (2014)
Anticholinergic Drugs Rescue Synaptic Plasticity in DYT1 Dystonia: Role of M1 Muscarinic Receptors
Marta Maltese et al.
MOVEMENT DISORDERS (2014)
Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders
P. Jeffrey Conn et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Muscarinic acetylcholine receptors: novel opportunities for drug development
Andrew C. Kruse et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Antipsychotic Drug-Like Effects of the Selective M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0152100
Nellie E. Byun et al.
NEUROPSYCHOPHARMACOLOGY (2014)
Pedunculopontine nucleus stimulation: where are we now and what needs to be done to move the field forward?
Hokuto Morita et al.
FRONTIERS IN NEUROLOGY (2014)
Genetics in Dystonia: An Update
Tania Fuchs et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2013)
Role of G(olf) in familial and sporadic adult-onset primary dystonia
Satya R. Vemula et al.
HUMAN MOLECULAR GENETICS (2013)
Mutations in GNAL cause primary torsion dystonia
Tania Fuchs et al.
NATURE GENETICS (2013)
Gait speed in Parkinson disease correlates with cholinergic degeneration
Nicolaas I. Bohnen et al.
NEUROLOGY (2013)
New genetic insights highlight 'old' ideas on motor dysfunction in dystonia
Rose E. Goodchild et al.
TRENDS IN NEUROSCIENCES (2013)
Effects of acetylcholine in the striatum Recent insights and therapeutic implications
Eduardo E. Benarroch
NEUROLOGY (2012)
Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior
Marina R. Picciotto et al.
NEURON (2012)
Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia
Carrie K. Jones et al.
NEUROPSYCHOPHARMACOLOGY (2012)
An allosteric enhancer of M4 muscarinic acetylcholine receptor function inhibits behavioral and neurochemical effects of cocaine
Ditte Dencker et al.
PSYCHOPHARMACOLOGY (2012)
Roles of the M1 Muscarinic Acetylcholine Receptor Subtype in the Regulation of Basal Ganglia Function and Implications for the Treatment of Parkinson's Disease
Zixiu Xiang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
The M1/M4 preferring agonist xanomeline reverses amphetamine-, MK801-and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia
Segev Barak et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2011)
Involvement of a Subpopulation of Neuronal M4 Muscarinic Acetylcholine Receptors in the Antipsychotic-like Effects of the M1/M4 Preferring Muscarinic Receptor Agonist Xanomeline
Ditte Dencker et al.
JOURNAL OF NEUROSCIENCE (2011)
Increased cocaine self-administration in M4 muscarinic acetylcholine receptor knockout mice
Lene S. Schmidt et al.
PSYCHOPHARMACOLOGY (2011)
Centrality of striatal cholinergic transmission in basal ganglia function
Paola Bonsi et al.
FRONTIERS IN NEUROANATOMY (2011)
Acetylcholine-dopamine balance hypothesis in the striatum: An update
Toshihiko Aosaki et al.
GERIATRICS & GERONTOLOGY INTERNATIONAL (2010)
Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease
Carine Karachi et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
A Subpopulation of Neuronal M4 Muscarinic Acetylcholine Receptors Plays a Critical Role in Modulating Dopamine-Dependent Behaviors
Jongrye Jeon et al.
JOURNAL OF NEUROSCIENCE (2010)
Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties
Katie Leach et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium
Benjamin Ray Miller et al.
FUTURE NEUROLOGY (2010)
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
P. Jeffrey Conn et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
History of falls in Parkinson disease is associated with reduced cholinergic activity
N. I. Bohnen et al.
NEUROLOGY (2009)
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders
P. Jeffrey Conn et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Re-emergence of striatal cholinergic interneurons in movement disorders
Antonio Pisani et al.
TRENDS IN NEUROSCIENCES (2007)
Levodopa-induced dyskinesias
Giovanni Fabbrini et al.
MOVEMENT DISORDERS (2007)
Quantitative changes in Gαolf protein levels, but not D1 receptor, alter specifically acute responses to psychostimulants
Jean-Christophe Corvol et al.
NEUROPSYCHOPHARMACOLOGY (2007)
M1 muscarinic receptors contribute to, whereas M4 receptors inhibit, dopamine D1 receptor-induced [3H]-Cyclic AMP accumulation in rat striatal slices
Enrique Sanchez-Lemus et al.
NEUROCHEMICAL RESEARCH (2006)
Muscarinic acetylcholine receptors
Masaru Ishii et al.
CURRENT PHARMACEUTICAL DESIGN (2006)
Selective cognitive dysfunction in acetylcholine M-1 muscarinic receptor mutant mice
SG Anagnostaras et al.
NATURE NEUROSCIENCE (2003)
Muscarinic M4 receptor inhibition of dopamine D1-like receptor signalling in rat nucleus accumbens
P Onali et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice
DJ Gerber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Golfα mediates dopamine D1 receptor signaling
XX Zhuang et al.
JOURNAL OF NEUROSCIENCE (2000)
Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice
HE Shannon et al.
SCHIZOPHRENIA RESEARCH (2000)
Muscarinic receptor antagonists in the treatment of overactive bladder
CR Chapple
UROLOGY (2000)
Share Paper
